Parker Aerospace Fuel Atomization Nozzles Selected by Vericor Power Systems for Use on TF50F Gas Turbine Engine
MiMedx Continues to Fight against Holding 2019 Annual Meeting
LUNA® Bar Continues Equality Conversation in Support of the Members of the U.S. Women’s National Soccer Team Players Association in Paris
Priceless Experiences Are Coming to a Smart Speaker Near You
Intel Announces Program for Israeli Startups Targeting Tech Inflections
Kemin Launches New Vision and Logo for the Future
L3 Achieves Record-High ISR Sensors Orders
L3 Introduces Production-Ready C-130 Avionics Modernization Solution for International C-130 Platforms
Media Alert: Cadence to Showcase Aerospace and Defense Solutions at the 2019 International Paris Air Show
Media Alert: Panasas Demonstrates a Frustration-Free HPC Storage Environment at ISC High Performance 2019
-
SeaWeb Delegates Tour Thai Union Feedmill to See World’s Most Sustainable Aquafeed in Production
--- Calysta joins Thai Union for field trip to Samut Sakhon feedmill --- MENLO PARK, Calif.--(BUSINESS WIRE)--Delegates attending last week’s SeaWeb Seafood Summit in Bangkok, Thailand, were given a sneak peek into how one of the world’s most sustainable aquafeed is produced and used. Thai Union Group PCL hosted a field trip to its Thai Union Feedmill in Samut Sakhon to show how the FeedKind® protein produced by Calysta is incorporated into feed – utilizing 10% FeedKind protein. The only marine ingredients remaining in the feed were Thai Union derived tuna byproducts and fish oil. The tour followed a partnership event at Seafood Expo Global in Brussels in May, where Thai Union offered the world its first taste of commercially reared shrimp fed FeedKind protein. Allan LeBlanc, Vice President and FeedKind Product Manager at Calysta, said: “The SeaWeb Seafood Summit brings together global leaders in seafood sustainability. It is exciting to see so many delegates interested in FeedKind and the role it can play in helping food producers meet the world’s growing demand for food without placing extra stress on our planet’s resources. “Results from trials conducted by Thai Union at this site have shown that, like other species fed FeedKind, shrimp enjoy a growth rate at least equal to conventional feeds. Trials have also pointed towards an improvement in feed conversion ratios over other feed products.” Darian McBain, Ph.D., Global Director of Corporate Affairs and Sustainability at Thai Union, said: “FeedKind meets a major part of our SeaChange® sustainability strategy in that it can bring a greater level of transparency and sustainability to aquaculture feed through the use of innovative alternative protein sources.” Calysta’s FeedKind is made via a patented natural-gas fermentation platform. Made using very little land and water by fermenting natural gas, an abundant source of energy, it is a safe, nutritious and traceable protein which has been commercially validated through extensive trials. For more information on Calysta, see www.calysta.com or www.FeedKind.com. More information on Thai Union’s sustainability strategy SeaChange® can be found at www.seachangesustainability.org About Calysta Calysta, Menlo Park, CA, is an innovator in sustainable products to improve worldwide food security. Calysta develops and commercializes FeedKind® protein, an alternative feed ingredient for fish, livestock and pet nutritional products. About Thai Union Group Thai Union Group PCL is the world's seafood leader bringing high quality, healthy, tasty and innovative seafood products to customers across the world for more than 40 years. Today, Thai Union is regarded as the world's largest producer of shelf-stable tuna products with annual sales exceeding THB 133.3 billion (US$ 4.1 billion) and a global workforce of over 47,000 people who are dedicated to pioneering sustainable, innovative seafood products. The company's global brand portfolio includes market-leading international brands such as Chicken of the Sea, John West, Petit Navire, Parmentier, Mareblu, King Oscar, and Rügen Fisch and Thai-leading brands SEALECT, Fisho, Qfresh, Monori, Bellotta and Marvo. As a company committed to innovation and globally responsible behaviour, Thai Union is proud to be a member of the United Nations Global Compact, and a founding member of the International Seafood Sustainability Foundation (ISSF). In 2015, Thai Union introduced its SeaChange® sustainability strategy. Find out more at seachangesustainability.org. Thai Union's on-going work on sustainability issues was recognized in 2018 by being ranked number one in the world in the Food Products Industry in the Dow Jones Sustainability Index, achieving a 100th percentile ranking for total sustainability score. Thai Union has now been named to the DJSI for five consecutive years. Thai Union was also named to the FTSE4Good Emerging Index for the third straight year in 2018. Contacts Contacts:Calysta: Steven Flanagan, sflanagan@webershandwick.com, +44(0)141.343.3250; Lyn Christenson, lyn@linkagesgroup.com, 650.492.6880, ex. 100. Thai Union: Leigh Murray, Leigh.Murray@thaiunion.com, +61.473.658.807
-
Bermuda Government, Industry Group Heads to Toronto
HAMILTON, Bermuda--(BUSINESS WIRE)--#Bermuda--Bermuda Finance Minister Curtis Dickinson leads a delegation of government, regulatory and industry representatives to Toronto next week to highlight Bermuda’s close links to Canada and opportunities for bilateral trade and investment. The delegation will take part in a one-day multi-industry forum, hosted by the Bermuda Business Development Agency (BDA) Wednesday, June 19 at The Ritz-Carlton Toronto, and also attend scheduled business development meetings around the city. Featuring informative panel discussions, thought-leadership sessions, and networking opportunities for investors and businesses interested in learning more about the island, the forum is the sixth in a series of overseas multi-industry showcases, following successful events in London, New York and Miami over the past two years. It is the first in Canada. “We’re looking forward to meeting civic leaders, media, investors and industry executives during the forum and related meetings,” said BDA CEO Andy Burrows. “The aim is to increase awareness of Bermuda as a gold-standard international financial centre and underscore our jurisdiction’s historic and mutually beneficial relationship with Canadian markets.” The Consul General of Canada in New York, Phyllis Yaffe, will help launch the forum with a fireside chat-style conversation with Minister Dickinson. Another highlight of the day will be a keynote presentation by Lucia Gallardo, a fintech entrepreneur who has partnered with the United Nations to leverage blockchain systems to help resettlement of refugees, among other projects. Industry sessions include participants from more than 30 Bermuda-related entities, among them, AMBIKA, Aon, Appleby, ArcTern Ventures, ASW Law, AXA XL, the Association of Bermuda Insurers & Reinsurers (ABIR); Bennett Jones, the Bermuda Insurance Management Association (BIMA), Bermuda Monetary Authority (BMA), Bermuda Tourism Authority (BTA), Butterfield Bank, ChainThat, Conyers, CryptoScan, Deloitte, Estera Services, Exponential Ventures, EY, Fasken, Insurance Bureau of Canada (IBC), KPMG, Kroll Bond Rating Agency, MQ Services, Outlier Canada, PwC, Quest Management Services, RGAx, SALT Lending, and Shyft Network. Canada is one of Bermuda’s most significant economic partners, with two-way trade between the two nations amounting to USD$2.6 billion in 2017, and $37 billion in mutual assets and investments. Bermuda supports an estimated 25,000 jobs in Canada, including 15,000 from multi-national companies in Bermuda and their Canadian affiliates and represents Canada’s fifth-largest export market in trade and services; only the US, UK, Germany and France are greater Canadian export markets. To register for the free, one-day forum, go to: http://bit.ly/TorontoForum CONNECTING BUSINESS The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial. Contacts MEDIA:Rosemary JonesHead of Communications & Marketingrosemary@bda.bm441 278-6558 or 441 337-4696
-
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Apple, Inc. To Contact The Firm
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Apple, Inc. (“Apple” or the “Company”) (NASDAQ:AAPL) of the June 17, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Apple stock or options between November 2, 2018 and January 2, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/AAPL. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Apple common stock between November 2, 2018 and January 2, 2019 (the “Class Period”). The case, City of Roseville Employees’ Retirement System v. Apple Inc., et al., No. 19-cv-2033 was filed on April 16, 2019. The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) the U.S.-China trade war had negatively impacted demand for iPhones and Apple’s pricing power in greater China; (2) due to Apple discounting the cost of replacement batteries to make up for the Company’s prior conduct of intentionally degrading the performance of the batteries in older iPhones, the rate at which Apple customers were replacing their batteries in older iPhones, rather than purchasing new iPhones, was negatively impacting Apple’s iPhone sales growth; (3) as a result of slowing demand, Apple had slashed production orders from suppliers for the new 2018 iPhone models and cut prices to reduce inventory; and (4) defendants’ decision to withhold unit sales for iPhones and other hardware, which was a metric relevant to investors and their view of the Company’s financial performance, was designed to and would mask declines in unit sales of the Company’s flagship product. On January 2, 2019, after the close of trading, Apple disclosed that, for the first time in 15 years, Apple would miss its prior quarterly revenue forecast amid falling iPhone sales in China, its third-largest market after the United States and Europe. The Company announced first quarter fiscal 2019 revenues of only $84 billion, far below the expected range of $89 billion to $93 billion the Company had announced just eight weeks earlier on November 1, 2018. The Company also admitted that in addition to macroeconomics in the Chinese market, the price cuts to battery replacements a year earlier to fix the Company’s prior surreptitious conduct had hurt iPhone sales. On this news, the Company's stock price fell from $157.92 per share on January 2, 2019 to $142.19 per share on January 3, 2019—a $15.62 or 9.96% drop. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Apple’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. Contacts FARUQI & FARUQI, LLP685 Third Avenue, 26th FloorNew York, NY 10017Attn: Richard Gonnello, Esq.rgonnello@faruqilaw.comTelephone: (877) 247-4292 or (212) 983-9330
-
Parker Cleveland Wheel & Brake New Upgrade Kit Is Now Available for Daher TBM 900 and TBM 930 Aircraft
New aftermarket conversion kit available exclusively from Parker features higher-strength design, lighter weight, and ease of maintenance PARIS, France--(BUSINESS WIRE)--#Aerospace--Parker Aerospace, a business segment of Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today announced the availability of its Cleveland Wheels & Brakes conversion kit for the Daher TBM 900, TBM 930, and the current production TBM 940 single-engine turboprop aircraft. Manufactured by the Parker Aerospace Aircraft Wheel & Brake Division, the conversion kit is stronger and lighter with many design improvements for easier maintenance. Additionally, the kits can also retrofit the TBM 700B, TBM700 C, TBM 850, TBM 900 aircraft, and current production TBM 910. Upgrade benefits over previous assembly Supported globally through Parker’s worldwide distribution network, the new wheel design features high-strength forging that has been optimized to provide a 14.7 percent weight reduction. Wheel enhancements also include the addition of rupture discs to help prevent accidental over-inflation of tires and a sleeker, bold design that better integrates with the stylish look of the Daher TBM 900/930 models. In terms of brake improvements, Parker redesigned the housing to be free of helical inserts and to incorporate wear-pin indicators, making tools unnecessary to check minimum wear-life thickness. In addition to a 3.7-percent weight reduction, the number of nuts and bolts used to fasten the torque tube and housing together is optimized for easier assembly and maintenance. Certification and availability The Aircraft Wheel & Brake Division received its technical standard order (TSO) authorization from the Federal Aviation Administration (FAA) for the aftermarket configuration of the wheels and brakes of the Daher TBM 900/930 models. In addition to being certified as a drop-in replacement assembly, the new wheels and brakes will also become the original equipment on the newly manufactured turboprops. “Daher’s TBM family of aircraft holds the distinction of being among the fastest single-engine production airplanes in existence while also being elegantly stylish,” said Parker Aircraft Wheel & Brake Business Team Leader Tom Dorinsky. “We are thrilled to provide owners and operators of these high-performance airplanes with a wheel and brake conversion kit that matches up to their standards.” The new conversion kit (P/N 199-291) is available now. For more information, or to obtain pricing and order the kit, please call the retailer of your choice, Aviall, or the Parker Wheel & Brake Division directly at 1-800-BRAKING (1-800-272-5464). The Parker Aerospace stand is in hall 5, stand #C210, at the Paris Air Show, June 17-23, 2019. About Parker Aerospace. Parker Aerospace is a global leader in the research, design, integration, manufacture, certification, and lifetime service of flight control, hydraulic, fuel and inerting, fluid conveyance, thermal management, lubrication, and pneumatic systems and components for aerospace and other high-technology markets. The company supports the world’s aircraft and aeroengine manufacturers, providing a century of experience and innovation for commercial and military aircraft. About Parker Hannifin. Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin. Contacts Brian KingParker Aerospace+1 (714) 458-7416brian.king@parker.com
-
CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic L
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE® (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia (CLL). The ASCEND trial compared CALQUENCE with the investigator’s choice of rituximab combined with idelalisib (IdR) or bendamustine (BR) in patients with relapsed or refractory CLL. At a median follow-up of 16.1 months, results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with CALQUENCE vs. IdR or BR, reducing the risk of disease progression or death by 69% (HR, 0.31: 95% CI, 0.20-0.49, p<0.0001). The median time without disease progression or death for patients treated with CALQUENCE has not yet been reached vs. 16.5 months in the control arm. At 12 months, 88% of patients on CALQUENCE showed no disease progression compared to 68% for the control arm. The safety and tolerability of CALQUENCE was consistent with its established profile. José Baselga, Executive Vice President, Oncology R&D said: “These data add to the growing body of evidence to support the profile of CALQUENCE as a selective BTK inhibitor that offers a chemotherapy-free treatment option with a favorable safety profile in chronic lymphocytic leukemia, a life-threatening disease. These data, along with our recent positive results from the Phase III ELEVATE-TN trial in previously-untreated chronic lymphocytic leukemia, will serve as the foundation for regulatory submissions later this year.” Paolo Ghia, MD, Professor, Medical Oncology, Università Vita-Salute San Raffaele in Milan, and investigator of the ASCEND trial, said: “This is the first randomized study to directly compare a BTK inhibitor as monotherapy with standard chemoimmunotherapy or idelalisib and rituximab combinations. With a significant improvement in progression-free survival and a favorable safety profile, acalabrutinib may become an important choice for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.” Safety overview: Most common (≥15%) AEs, n (%) CALQUENCE (N = 154) IdR (N = 118) BR (N = 35) Any Grade ≥3 Any Grade ≥3 Any Grade ≥3 Headache 34 (22%) 1 (1%) 7 (6%) 0 0 0 Neutropenia 30 (19%) 24 (16%) 53 (45%) 47 (40%) 12 (34%) 11 (31%) Diarrhea 28 (18%) 2 (1%) 55 (47%) 28 (24%) 5 (14%) 0 Anemia 23 (15%) 18 (12%) 11 (9%) 8 (7%) 4 (11%) 3 (9%) Cough 23 (15%) 0 18 (15%) 1 (1%) 2 (6%) 0 Pyrexia 19 (12%) 1 (1%) 21 (18%) 8 (7%) 6 (17%) 1 (3%) Fatigue 15 (10%) 2 (1%) 10 (8%) 0 8 (23%) 1(3%) Nausea 11 (7%) 0 15 (13%) 1 (1%) 7 (20%) 0 IRR* 0 0 9 (8%) 2 (2%) 8 (23%) 1 (3%) Events of clinical interest for CALQUENCE Atrial fibrillation 8 (5%) 2 (1%) 4 (3%) 1 (1%) 1 (3%) 1 (3%) Bleeding 40 (26%) 3 (2%) 9 (8%) 3 (3%) 2 (6%) 1(3%) Hypertension 5 (3%) 3 (2%) 5 (4%) 1 (1%) 0 0 SPM** excluding NMSC*** 10 (6%) 5 (3%) 3 (3%) 0 1 (3%) 1 (3%) *Infusion related reaction **Secondary primary malignancy ***Non-melanoma skin cancer. AstraZeneca recently announced that the Phase III ELEVATE-TN trial met its primary endpoint at interim analysis in patients with previously-untreated CLL and that full results will be reported at a forthcoming medical meeting. IMPORTANT SAFETY INFORMATION ABOUT CALQUENCE (acalabrutinib) Hemorrhage Serious hemorrhagic events, including fatal events, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with CALQUENCE monotherapy. Grade 3 or higher bleeding events, including gastrointestinal, intracranial, and epistaxis, have been reported in 2% of patients. Overall, bleeding events, including bruising and petechiae of any grade, occurred in approximately 50% of patients with hematological malignancies. The mechanism for the bleeding events is not well understood. CALQUENCE may further increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies, and patients should be monitored for signs of bleeding. Consider the benefit-risk of withholding CALQUENCE for 3 to 7 days pre- and post-surgery, depending upon the type of surgery and the risk of bleeding. Infection Serious infections (bacterial, viral, or fungal), including fatal events and opportunistic infections, have occurred in the combined safety database of 612 patients with hematologic malignancies treated with CALQUENCE monotherapy. Grade 3 or higher infections occurred in 18% of these patients. The most frequently reported Grade 3 or 4 infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML) have occurred. Monitor patients for signs and symptoms of infection and treat as medically appropriate. Consider prophylaxis in patients who are at increased risk for opportunistic infections. Cytopenias In the combined safety database of 612 patients with hematologic malignancies, patients treated with CALQUENCE monotherapy experienced Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (11%), and thrombocytopenia (8%), based on laboratory measurements. Monitor complete blood counts monthly during treatment. Second Primary Malignancies Second primary malignancies, including non-skin carcinomas, have occurred in 11% of patients with hematologic malignancies treated with CALQUENCE monotherapy in the combined safety database of 612 patients. The most frequent second primary malignancy was skin cancer, reported in 7% of patients. Advise protection from sun exposure. Atrial Fibrillation and Flutter In the combined safety database of 612 patients with hematologic malignancies treated with CALQUENCE monotherapy, atrial fibrillation and atrial flutter of any grade occurred in 3% of patients, and Grade 3 in 1% of patients. Monitor for atrial fibrillation and atrial flutter and manage as appropriate. ADVERSE REACTIONS The most common adverse reactions (≥20%) of any grade were anemia,* thrombocytopenia,* headache (39%), neutropenia,* diarrhea (31%), fatigue (28%), myalgia (21%), and bruising (21%). *Treatment-emergent decreases (all grades) of hemoglobin (46%), platelets (44%), and neutrophils (36%) were based on laboratory measurements and adverse reactions. The most common Grade ≥ 3 non-hematological adverse reaction (reported in at least 2% of patients) was diarrhea (3.2%). Dosage reductions or discontinuations due to any adverse reaction were reported in 1.6% and 6.5% of patients, respectively. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 4.8% of patients. DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid co-administration with a strong CYP3A inhibitor. If a strong CYP3A inhibitor will be used short-term, interrupt CALQUENCE. Moderate CYP3A Inhibitors: When CALQUENCE is co-administered with a moderate CYP3A inhibitor, reduce CALQUENCE dose to 100 mg once daily. Strong CYP3A Inducers: Avoid co-administration with a strong CYP3A inducer. If a strong CYP3A inducer cannot be avoided, increase the CALQUENCE dose to 200 mg twice daily. Gastric Acid Reducing Agents: If treatment with a gastric acid reducing agent is required, consider using an H2-receptor antagonist or an antacid. Take CALQUENCE 2 hours before taking an H2-receptor antagonist. Separate dosing with an antacid by at least 2 hours. Avoid co-administration with proton pump inhibitors. Due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with CALQUENCE. SPECIFIC POPULATIONS There is insufficient clinical data on CALQUENCE use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if CALQUENCE is present in human milk. Advise lactating women not to breastfeed while taking CALQUENCE and for at least 2 weeks after the final dose. Please see complete Prescribing Information including Patient Information. – ENDS – NOTES TO EDITORS About ASCEND ASCEND (ACE-CL-309) is a global, randomized, multicenter, open-label Phase III trial evaluating the efficacy of CALQUENCE in previously-treated patients with CLL.2 In the trial, 310 patients were randomized (1:1) into two arms. Patients in the first arm received CALQUENCE monotherapy (100mg twice daily until disease progression). Patients in the second arm received investigator’s choice of either rituximab in combination with idelalisib or rituximab in combination with bendamustine.1,2 The primary endpoint is PFS assessed by an independent review committee (IRC), and key secondary endpoints include investigator-assessed PFS, IRC- and investigator-assessed overall response rate (ORR) and duration of response (DOR), as well as overall survival (OS), patient reported outcomes (PROs) and time to next treatment (TTNT).1,2 About CALQUENCE CALQUENCE® (acalabrutinib) was granted accelerated approval by the US Food and Drug Administration (FDA) in October 2017 for the treatment of adult patients with MCL who have received at least one prior therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. CALQUENCE is an inhibitor of Bruton tyrosine kinase (BTK). CALQUENCE binds covalently to BTK, thereby inhibiting its activity.3 In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. As part of an extensive clinical development program, AstraZeneca and Acerta Pharma are currently evaluating CALQUENCE in 26 clinical trials that are company sponsored. CALQUENCE is being developed for the treatment of multiple B-cell blood cancers including CLL, MCL, diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, and multiple myeloma and other blood cancers. Beyond the positive Phase III clinical trials ASCEND and ELEVATE-TN, other Phase III trials in CLL are ongoing, including ELEVATE-RR (ACE-CL-006) evaluating acalabrutinib vs. ibrutinib in previously treated high-risk CLL and ACE-CL-311 evaluating acalabrutinib in combination with venetoclax and with/without obinutuzumab with previously-untreated CLL without 17p deletion or TP53 mutation. About chronic lymphocytic leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with an estimated 191,000 new cases globally and 20,720 new cases in the US annually, and prevalence that is expected to grow with improved treatment.4-7 In CLL, too many blood stem cells in the bone marrow become abnormal lymphocytes and these abnormal cells have difficulty fighting infections.4 As the number of abnormal cells grows there is less room for healthy white blood cells, red blood cells and platelets.4 This could result in anemia, infection and bleeding.4 B-cell receptor signaling through BTK is one of the essential growth pathways for CLL. About AstraZeneca in hematology Leveraging its strength in oncology, AstraZeneca has established hematology as one of four key oncology disease areas of focus. The Company’s hematology franchise includes two US FDA-approved medicines and a robust global development program for a broad portfolio of potential blood cancer treatments. Acerta Pharma serves as AstraZeneca’s hematology research and development arm. AstraZeneca partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need. In October 2018, AstraZeneca and Innate Pharma announced a global strategic collaboration that included Innate Pharma licensing the US commercial rights of LUMOXITI™ (moxetumomab pasudotox-tdfk), and with support from AstraZeneca, will continue EU development and commercialization, pending regulatory submission and approval. About AstraZeneca in oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in hematology. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS. References 1 Ghia P, Pluta A, Wach M, et al. ASCEND Phase 3 study of acalabrutinib vs. investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Abstract LB2606 at: European Hematology Association 2019 Annual Meeting. Available online. Accessed June 2019. 2 ClinicalTrials.gov. A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL. NCT02970318. Available online. Accessed June 2019. 3 CALQUENCE® (acalabrutinib) Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 4 National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version. Available online. Accessed June 2019. 5 Global Burden of Disease Cancer Collaboration. JAMA Oncol. 2017;3(4):524-528. 6 National Institute of Health SEER Program. Cancer Stat Facts: Leukemia—Chronic Lymphocytic Leukemia (CLL). Available online. Accessed June 2019. 7 Jain N, et al. Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies. Blood. 2015;126:871. US-28693 Last Updated 5/19 Contacts Media InquiriesMichele Meixell +1 302 885 2677Stephanie Wiswall +1 302 885 2677
-
Three Finalists Selected Following GA-ASI’s Blue Magic Belgium Event
PARIS--(BUSINESS WIRE)--Three finalists have been selected from GA-ASI’s Blue Magic Belgium event with the goal of supporting GA-ASI and the development of MQ-9B SkyGuardian Remotely Piloted Aircraft (RPA) for Belgium. The three Belgian companies selected are AIRobot, ALX Systems, and Hexagon. AIRobot, a company based at DronePort in Sint Truiden, Belgium, focuses on developing drone performance equipment for easy, precise and safe professional operations, while specializing in Artificial Intelligence (AI) for processing hyper-spectral imagery. ALX Systems is an Unmanned Aircraft System (UAS) solution provider based in Liège, Belgium and specializing in AI for processing Full Motion Video. Hexagon’s Geospatial division, with an office in Leuven, Belgium, specializes in software solutions and geospatial tools for visualizing location intelligence, such as auto-routing UAS and creating a smart digital reality. GA-ASI held outreach events in Belgium May 15-16 with the goal of identifying small to medium-sized Belgian companies that can support SkyGuardian development through cutting-edge technologies. This followed the Government of Belgium’s approval for Belgian Defense to negotiate acquisition of GA-ASI’s SkyGuardian to meet the nation’s RPA requirements. “We were very impressed by the many talented companies and particularly by the innovative concepts presented by these three finalists,” said Linden Blue, CEO, GA-ASI. Blue Magic Belgium was a Research and Development (R&D) event held in two regions of Belgium. Approximately 50 related companies registered for the event and 19 companies were selected to present their innovative technologies to a technical panel of experts from GA-ASI. GA-ASI is committed to placing $3 million in R&D funding with Belgium industry. This investment will focus on high-value technological development with small to medium-sized enterprises. The seed funds will be utilized to develop Belgian capabilities that meet Ministry of Defense (MOD) and industry objectives to be competitive in future European RPA programs. About GA-ASI General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than five million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com. Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc. Contacts Robert WalkerGeneral Atomics Aeronautical Systems, Inc.+1 (858) 524-8101ASI-MediaRelations@ga-asi.com
-
World’s First E-Money License for Blockchains Issued to Monerium
Announcement to be made at The Future of Money: Central Bank Digital Currency Conference in Stockholm REYKJAVIK, Iceland--(BUSINESS WIRE)--#Blockchain--Monerium ehf. has received a license from the Financial Supervisory Authority of Iceland to issue e-money on blockchains through its subsidiary, Monerium EMI ehf. The full license is the world’s first e-money license for blockchains issued under EU e-money regulations. The license is passportable within the largest global economic zone, the European Economic Area, and to external jurisdictions subject to regulatory approval and destination country regulations. Designed as a digital alternative to cash, e-money is a proven framework for digital fiat currency already in use for pre-paid cards and mobile wallets. By issuing e-money on blockchains, Monerium removes the need for intermediaries and provides the ability to automate financial transactions in many sectors, including payments, trade finance, securities settlement, and ecommerce. At the same time, e-money on blockchains extends Satoshi Nakamoto’s vision of online peer-to-peer currency transactions to a regulated form of digital fiat currency. Founded in 2015 by four repeat entrepreneurs with experience from finance and technology, Monerium has received seed investments from ConsenSys, Crowberry Capital, and private investors. Prior to the e-money application, the company founders authored a commissioned report on blockchains and financial services for an European financial institution and developed a pilot for tokenizing fiat currency in collaboration with ConsenSys. Jon Helgi Egilsson, co-founder, chairman and former chairman of the supervisory board of the Central Bank of Iceland, will announce the license in Stockholm on June 15 at The Future of Money: Central Bank Digital Currency Conference, saying, "Monerium e-money encompasses the benefits of programmable money on blockchain, in addition to being the closest form of central bank money there is - based on a proven EU regulatory framework." “Receiving an e-money license is a major milestone towards achieving our goal of making digital currency accessible, secure, and simple to transact,” states Sveinn Valfells, CEO and co-founder. “To support our e-money issuance, we have developed a digital banking platform that is compatible with all leading blockchain protocols and extensible to other clients and financial services. Our platform is based on open standards and designed to support decentralized financial applications.” Monerium is currently entering closed beta with initial customers and partners. The company plans to partner with distributed application developers and blockchain platform providers to make e-money available to consumers and enterprises across borders and protocols. Together with Monerium CTO and co-founder Gisli Kristjánsson, Valfells will announce the closed beta and partnership programs at Copenhagen FinTech Week on June 18th. About Monerium Monerium is a financial technology company with the mission of making digital currency accessible, secure, and simple to transact. Using Monerium e-money, individuals and non-financial enterprises can store and send digital currency on blockchains without going through traditional financial institutions. Monerium was founded in 2015 by a team with diverse backgrounds, including central banking, finance, blockchain, and cloud services. The company has raised $2M in funding from ConsenSys, Crowberry Capital, Hof Holdings, and private investors. Contacts For media enquiries:Chris McClure, +1 (580) 448-2841press@monerium.com
-
Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
24-week results demonstrate significant improvement in repigmentation of facial vitiligo lesions after treatment with ruxolitinib cream Data presented at the World Congress of Dermatology support the planned initiation of a pivotal Phase 3 program, for which preparations are currently underway Investor conference call and webcast scheduled for Monday, June 17 at 8 a.m. EDT WILMINGTON, Del.--(BUSINESS WIRE)--$INCY #wcd2019--Incyte (Nasdaq:INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream). F-VASI50 response was most notably achieved with ruxolitinib cream 1.5 percent administered once daily (QD) and twice daily (BID) vs. vehicle control (50 percent and 45 percent vs. 3 percent, respectively; P<0.001). These results are being presented at the 24th World Congress of Dermatology (WCD) in Milan, Italy, during a late-breaking research session today, June 15, 2019, from 9:25 a.m. CET to 9:35 a.m. CET (3:25 a.m. EDT to 3:35 a.m. EDT). (Location: Room Yellow 3). “The positive 24-week data presented at the World Congress of Dermatology support the potential of ruxolitinib cream to offer a novel treatment option for patients with this chronic autoimmune disease,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “For patients who choose to seek treatment for their vitiligo, current options are often limited by inadequate efficacy or potential side effects. We look forward to advancing ruxolitinib cream into Phase 3 development for vitiligo in the hope that it may become the first approved treatment for what can be a life-altering disease.” Key 24-week results include: Significantly more patients achieved F-VASI50 after 24 weeks of treatment with all ruxolitinib cream regimens compared to the vehicle control. The highest F-VASI50 response was achieved with ruxolitinib cream 1.5 percent QD and BID compared to vehicle control (50 percent and 45 percent vs. 3 percent, respectively; P<0.001). A ≥75 percent improvement from baseline in the facial vitiligo area severity index score was achieved by 17 percent, 30 percent, and 0 patients treated with ruxolitinib cream 1.5 percent QD, BID, and vehicle cream, respectively. Facial Physician Global Vitiligo Assessment (F-PhGVA) scores of clear (no signs of vitiligo) or almost clear (only specks of depigmentation present) skin were achieved by 13 percent, 9 percent, and 0 patients receiving ruxolitinib cream 1.5 percent QD, BID, and vehicle cream, respectively. Ruxolitinib cream was generally well-tolerated at all dosage strengths. Over-activity of the JAK signaling pathway has been shown to drive inflammation involved in the pathogenesis and progression of vitiligo. These data on ruxolitinib cream, a JAK inhibitor, support the planned initiation of pivotal Phase 3 development later in 2019, for which preparations are already underway. “As a physician, I am looking for safe and effective options that may help my patients achieve their treatment goals,” said David Rosmarin, M.D., Assistant Professor at the Tufts University School of Medicine. “I am encouraged by these clinical trial results and the potential of ruxolitinib cream to become an important treatment option for the repigmentation of vitiligo lesions.” About Vitiligo Vitiligo is a chronic, immune-mediated skin disease that is estimated to affect between 2 and 3 million people in the U.S. and for which there is no known cure. It can occur at any age, although many people experience vitiligo symptoms before the age of 20. Vitiligo is characterized by the progressive loss of pigmentation in patches of skin across the body, causing the skin to appear lighter. This occurs when pigment-producing cells known as melanocytes are destroyed or stop functioning. Vitiligo can affect any area of skin on the body and may also affect hair, eyes or the inside of the mouth. The exact cause of vitiligo is unknown, though recent research suggests that changes in the immune system may be responsible for the disease. About the Study The safety and efficacy of ruxolitinib cream were evaluated in an Incyte-sponsored randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study (NCT03099304), which began in April 2017. The Phase 2 study program is comprised of three parts spanning 104 weeks. The first part of the study – the findings for which are being presented at the 24th WCD – spanned 24 weeks and enrolled 157 adults (aged 18-75 years) diagnosed with vitiligo and with depigmented areas of at least 0.5 percent of the body surface area (BSA) on the face and at least 3 percent of the total BSA on nonfacial areas. Patients were equally randomized across five treatment arms, including: ruxolitinib cream 1.5 percent, 0.5 percent or 0.15 percent administered QD; ruxolitinib cream 1.5 percent administered BID; or vehicle control for 24 weeks. The primary efficacy endpoint was the percentage of patients treated with ruxolitinib cream who achieved F-VASI50 score at Week 24, compared to patients treated with vehicle control. Key secondary endpoints included the proportion of patients who achieved a F-PhGVA score of 0 or 1 at Week 24 and the safety and tolerability of ruxolitinib cream. For more information about the study, please visit: https://clinicaltrials.gov/ct2/show/NCT03099304 About Ruxolitinib Cream Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of patients with mild to moderate atopic dermatitis (TRuE-AD) with results expected in the first half of 2020, and is expected to enter Phase 3 development for the treatment of certain patients with vitiligo (TRuE-V) in the second half of 2019. Incyte has worldwide rights for the development and commercialization of ruxolitinib cream. Conference Call Information Incyte will host an investor conference call and webcast at 8:00 a.m. EDT on Monday, June 17, 2019—the call and webcast can be accessed via the Events and Presentations tab of the Investor section of www.incyte.com. To access the conference call on Monday, June 17, 2019, please dial 877-407-3042 for domestic callers or +1-201-389-0864 for international callers. When prompted, provide the conference identification number, 13689599. If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1-201-612-7415. To access the replay you will need the conference identification number, 13689599. About Incyte Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte. Forward Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s plans to initiate a Phase 3 program for ruxolitinib cream in vitiligo, the timing and potential results of such a Phase 3 program, the potential for ruxolitinib cream to be an effective treatment option for patients with vitiligo and whether or when ruxolitinib cream will be approved for the treatment of vitiligo, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending March 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements. Contacts MediaCatalina Loveman+1 302 498 6171cloveman@incyte.com InvestorsMichael Booth, DPhil+1 302 498 5914mbooth@incyte.com
-
APPLE 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until June 17, 2019 to file lead plaintiff applications in a securities class action lawsuit against Apple Inc. (NasdaqGS: AAPL). Investor losses must relate to purchases of the Company’s shares between November 2, 2018 and January 2, 2019. This action is pending in the United States District Court for the Northern District of California. What You May Do If you purchased shares of Apple and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-aapl/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by June 17, 2019. About the Lawsuit On January 2, 2019, post-market, the Company disclosed that it would miss its prior quarterly revenue forecast by up to $9B, with revenues of only $84B, far below prior guidance of $89B to $93B, due in part to falling iPhone sales in China and significantly reduced battery replacement pricing. On this news, the price of Apple’s shares fell, damaging investors. The case is City of Roseville Employees’ Retirement System v. Apple Inc., et al., No. 19-cv-2033. About Kahn Swick & Foti, LLC KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com. Contacts Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.kahn@ksfcounsel.com1-877-515-1850
-
INTUIT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Intuit Inc. - I
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Intuit Inc. (NasdaqGS: INTU). For many years, the Company operated under an agreement with the Internal Revenue Service to provide a free version of its commercial tax filing products called TurboTax “Freedom Edition” to low-income taxpayers in exchange for the IRS agreeing not to compete by offering its own free online tax filing service. However, the Company has recently been sued in a consumer class action lawsuit alleging that it defrauded taxpayers through a scheme to deliberately hide or otherwise limit access to its free service, while aggressively marketing another program as free even though it had limited functionality and deceived users otherwise eligible for free filing into paying for product upgrades to file their taxes. KSF’s investigation is focusing on whether Intuit’s officers and/or directors breached their fiduciary duties to Intuit’s shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Intuit shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-intu/ to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com. Contacts Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.kahn@ksfcounsel.com1-877-515-1850
-
Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Zuora, Inc. Investors (ZUO)
LOS ANGELES--(BUSINESS WIRE)--$ZUO #classaction--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Roberts v. Zuora, Inc. et al., (Case No. 3:19-CV-03422), on behalf of persons and entities that purchased or otherwise acquired Zuora, Inc. (NYSE: ZUO) (“Zuora” or the “Company”) securities between April 12, 2018 and May 30, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. If you are a shareholder who suffered a loss, click here to participate. On May 30, 2019, the Company lowered its fiscal 2020 revenue guidance to a range of $268 million to $278 million, from prior guidance of $289 million to $293.5 million, citing problems integrating RevPro, as well as sales execution problems. On this news, the Company’s share price fell $5.91, or nearly 30%, to close at $13.99 on May 31, 2019, thereby injuring investors. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company would focus on implementing RevPro for new customers ahead of the deadline to comply with accounting standard ASC 606; (2) that, as a result, the Company lacked adequate resources to integrate RevPro with the core business; (3) that the Company would focus on RevPro integration a year after the acquisition closed; (4) that delays in integrating RevPro would materially impact the business; (5) that the market for RevPro was limited to customers seeking to implement new accounting standards such as ASC 606; (6) that, after the deadline for ASC 606 compliance passed, demand for RevPro was reasonably likely to decline; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Follow us for updates on Twitter: twitter.com/GPM_LLP. If you purchased Zuora securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay and Murray LLP, Los AngelesLesley Portnoy, 310-201-9150 or 888-773-9224www.glancylaw.comshareholders@glancylaw.com
-
Delays on Ebola = Death
As Ebola spreads to Uganda, WHO continues to delay declaring an international emergency in the face of a devastating crisis—the WHO, UN, AU and DRC must do more to end the current outbreak! WASHINGTON--(BUSINESS WIRE)--Amid a disastrous Ebola outbreak in the Democratic Republic of the Congo (DRC), AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO), United Nations (UN), African Union (AU) and DRC government to cast politics aside and take immediate actions to ensure the most aggressive response possible in defeating the epidemic, including declaring an international emergency and utilizing all available vaccines. There is a dire situation on the ground in the DRC—and now in Uganda. Public distrust of outside personnel and support is hindering the identification and vaccination of Ebola contacts, available vaccine stockpiles are steadily dwindling and not being used as they should, and the WHO, UN, AU and DRC actions have so far have proven to be insufficient in containing and extinguishing the current crisis. “This outbreak threatens the entire continent and the world—WHO must declare a Public Health Emergency of International Concern,” said AHF President Michael Weinstein. “That will allow increased funding, personnel and resources to be dedicated to a response that is severely lacking thus far. Inspired and aggressive leadership is also needed at top levels of the agencies and governments conducting response efforts—we cannot expect a different result if the same inadequate measures are continually implemented.” With over 2,000 cases and nearly 1,400 deaths since last August, the current Ebola outbreak is killing at a horrifying rate of almost 70%. And even though individuals in the affected areas are pleading to be vaccinated, stockpiles of one vaccine are running dangerously low and confidential sources report that the other is not being used at all due to disputes within the DRC government. “There is nothing more critical in this response than the availability of vaccines that have been proven to work, and it’s incomprehensible that they are available and not being utilized—especially now that Ebola has crossed into Uganda,” said AHF Africa Bureau Chief Dr. Penninah Iutung. “The WHO and the African Union must take the lead and insist that all available vaccines be used, and the Congolese government must forget its political in-fighting and ensure that stockpiles are available immediately to all who need them.” “We [AHF] lost one of our own doctors in West Africa’s Ebola outbreak in 2014 that killed over 11,000 people—and now our staff and patients in Uganda are being threatened,” added Dr. Iutung. “It is critical, now more than ever, that the WHO, UN, AU and DRC do all they can to stop this outbreak in its tracks. Take more action now – before it’s too late!” AHF encourages you to experience the sobering truth behind the 2014 Ebola outbreak in this short documentary and see the devastation that occurs when outbreak preparedness is not a top global health priority. For more information, please contact Ged Kenslea at gedk@aidshealth.org or (323) 791-5526. About AIDS Healthcare Foundation (AHF) AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.1 million people in 43 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare. Contacts US MEDIA CONTACTS:Ged Kenslea, Senior Director, Communications, AHF+1 323 308 1833 work +1.323.791.5526 mobilegedk@aidshealth.org Denys Nazarov, Director of Global Policy &Communications, AHF+1 323 219 1091dn@aidshealth.org
-
Golden Agri-Resources: Latest Greenpeace Report Ignores Progress Being Made in Palm Sector
SINGAPORE, June 15, 2019 /PRNewswire/ -- Golden Agri-Resources (GAR) believes Greenpeace's latest press statement, released on 11 June 2019 entitled "50 million hectares destroyed as companies disregard zero deforestation pledge", fails to give an accurate picture of the transformation underway across the palm oil industry. Specifically, we believe Greenpeace falsely states that GAR and other leading palm oil traders are not mapping and monitoring suppliers via satellites and taking meaningful action to halt deforestation and implement more sustainable production practices. Since introducing the GAR Social and Environmental Policy in 2015, traceability and increasing transparency of our own operations and our supply chain has been a core component of GAR's sustainability effort. For four years, GAR has been carrying out a major traceability exercise. The company has been fully traceable to the mill since 2015, and 100 percent traceable to the plantation (TTP) for all GAR-owned mills since end of 2017. Beyond our direct operations we have convinced our third-party suppliers to join us in this important exercise. These efforts are bearing fruit and to date we have achieved over 60 percent TTP for our palm supply chain, keeping us on track to hit full TTP by end-2020. This progress is regularly reported to our stakeholders and our supply chain traceability data is available to the public on our Sustainability Dashboard. GAR's efforts have been recognised with a variety of awards including, most recently, the ADB DutchCham Winsemius Award for Manufacturing and Supply Chains. Currently, GAR is collaborating with customers to trial satellite monitoring systems such as Starling, which can help monitor forest cover change in some key areas. We are also supporting World Research Institute initiatives such as the GFW Pro tool which will enable companies, banks and organisations to analyse and manage deforestation risk within their supply chains. Monitoring is a key starting point, but the transformation of our supply chain requires us to go beyond technology and take a constructive engagement approach to help our suppliers become more responsible, including investigating why deforestation has taken place and who is responsible. To date, through deep engagement, encouragement and sharing of best practices we are supporting the conservation of 65,000 hectares of HCSA forests by our suppliers. Business commitments and interventions, alongside government actions, are starting to show results. Deforestation in Indonesia has shown another year of sharp decline, according to the WRI which has reported a 40 percent reduction in loss of primary forests in Indonesia compared to 2002-2016 figures and a 45 percent reduction in the loss of peat forest areas. In ignoring this progress and suggesting palm oil producers are not taking their responsibilities to not only forest conservation but also farmer and supplier livelihoods seriously, Greenpeace perpetuates the negative narrative associated with the industry, fails to recognise the work underway to bring change and risks undermining those efforts. View original content:http://www.prnewswire.com/news-releases/golden-agri-resources-latest-greenpeace-report-ignores-progress-being-made-in-palm-sector-300868121.html
-
Food Lion Receives National Recognition for CIAA Campaign
Retailer Takes Top Public Relations Honors for its #BallinOnHunger Social Impact Initiative SALISBURY, N.C.--(BUSINESS WIRE)--Public Relations Society of America has awarded Food Lion with its prestigious Bronze Anvil Award in recognition of its successful #BallinOnHunger campaign executed during the Central Intercollegiate Athletics Association Tournament. The purpose of the 2018 campaign was to spark engagement with CIAA fans and connect them with ways they could help Food Lion fight hunger in the 12 towns and cities where there are CIAA schools. The result was enough social posts to donate 24,000 meals to local food banks and more than 2.9 million of media impressions giving visibility to campaign and the Food Lion brand. Judges commented that the campaign “was an excellent effort that made a real difference. The entry was well thought out and clearly articulated the purpose of this campaign.” For more than 45 years, the Bronze Anvil Awards have recognized the best of the best in public relations tactics -- the use of social media, video, blogs, podcasts, annual reports, digital newsletters, websites – that contribute to the success of overall programs or campaigns. Judging is performed across the United States by teams of PRSA members and others with expertise in the specific categories. Only one Bronze Anvil was awarded in 33 categories. The awards were presented in New York City, N.Y., last Thursday. This is the company’s first time winning a Bronze Award and third time winning a PRSA national award. About Food Lion Food Lion, based in Salisbury, N.C., since 1957, has more than 1,000 stores in 10 Southeastern and Mid-Atlantic states and employs more than 63,000 associates. By leveraging its longstanding heritage of low prices and convenient locations, Food Lion is working to own the easiest full shop grocery experience in the Southeast, anchored by a strong commitment to affordability, freshness and the communities it serves. Through Food Lion Feeds, the company has donated more than 500 million meals to individuals and families in need since 2014. Food Lion is a company of Ahold Delhaize USA, the U.S. division of Zaandam-based Royal Ahold Delhaize Group. For more information, visit www.foodlion.com. Contacts Kelly Powell704-310-3886kelly.powell@foodlion.com
-
INVESTOR ALERT: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eros International Plc
NEW YORK--(BUSINESS WIRE)--$EROS #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Eros International Plc (“Eros” or the “Company”) (NYSE: EROS). This investigation concerns whether Eros has violated federal securities laws and/or engaged in other unlawful business practices. On June 5, 2019, Eros’s majority owned subsidiary Eros International Media’s long-term bank facilities rating was cut by 10 notches to D from BBB- following “ongoing delays/default in debt servicing due to a slowdown in collection from debtors.” On this news, Eros’s share price fell $3.59, approximately 49%, to close at $3.71 on June 6, 2019. Then, on June 7, 2019, Hindenburg Research published an article explaining that the credit downgrade was due to “multiple undisclosed related-party transactions that appear designed to hide receivables,” and that “a significant portion of Eros’s receivables don’t exist.” On this news, Eros’s share price fell $0.41, approximately 11%, to close at $3.30 on June 7, 2019. If you acquired Eros securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you. Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Kirby McInerney LLPThomas W. Elrod, Esq., (212) 371-6600investigations@kmllp.comwww.kmllp.com
-
29 Indonesian businesses win SME100 Awards as 'Fast Moving Companies 2019'
The SME100 Awards 2019 named 29 Indonesian SMEs as 'Fast Growing Companies' in Jakarta, June 14.JAKARTA, Jun 15, 2019 - (ACN Newswire) - The prestigious award for small and medium enterprises, the SME100 Awards, recognized 29 Indonesian SMEs honored as 'Fast Growing Businesses 2019' in a ceremony in Jakarta on Friday.The naming of 29 SMEs as fast growing businesses was based on evaluating criteria, such as income and profit growth, along with business prospects, investments in training, and research and development efforts.Group publisher and editor-in-chief of SME Magazine William Ng said SME100 surveyed 2,000 leading small and medium businesses in Indonesia from February to April 2019.This program was created in collaboration with the Indonesian Chamber of Commerce and Industry (Kadin) and the Indonesia Business Council for Sustainable Development (IBCSD), he said.According to Ng, the involvement of SMEs in Indonesia can help ensure the country's economic growth, noting that SMEs continued to grow, despite an unpredictable global economy and tougher market challenges.Some of the SMEs surveyed by SME100 recorded income growth of up to 9.4 percent and increases in profits of up to 23.5 percent in 2018, fueled by domestic consumption."Although those companies winning the 'Fast Moving Companies 2019' awards may not represent all SMEs, they eliminate the myth that business is difficult for SMEs in Indonesia," he said.Among the winners were chatbot provider Kata ai, Kebab franchisor Baba Rafi, wedding and vacation service Weddingku group, platform financial peer-to-peer Investree, digital wallet provider Payfazz, and lifestyle retailer Metroxgroup.Indonesia is the third ASEAN member state to organize SME100 Awards, after Malaysia and Singapore. SME100 Award Winners Indonesia :1. IMyCo (Agatha Pratama) - http://www.imycoindonesia.co.id/2. Francis (Anurerah Citra Rasa) - http://www.francisartisanbakery.com/3. Ticket To The Moon (PT Ayunan Bulanan International) - https://www.ticketothemoon.com/4. Baba Rafi (PT Kebab Baba Rafi) - http://www.babarafi.com/5. Beema Honey (Beema Honey) - https://www.beemahoney.com/6. Black Kebab (CV Black Kebab Indonesia) - https://blackkebab.com/7. Cekindo (Cekindo Business Inbternational) - https://www.cekindo.com/8. MEDCOM.ID (PT Citra Mulimedia Indonesia) - https://www.medcom.id/9. David Roy (PT David Roy International) - http://drindonesia.com/10. Damn! I Love Indonesia (PT Dnamica Anak Muda Nasional) - https://damniloveindonesia.com/11. DOKU (PT Nusa Satu Inti Artha) - https://www.doku.com/12. AQUATEC (PT Gani Arta Dwitunggal) - https://www.ganiarta.com13. GENDHIS (PT Gendhis Bag) - https://www.gendhisbag.com14. Globalresources Corporation (Global Resource Trader Corp) - http://globalresourcestradercorp.com/15. investree(PT Investree Radhika Jaya) - https://www.investree.id/ 16. Kata.ai (PT Yesboss Group Indonesia) - https://kata.ai/17. LalaMove (Lalamove Indonesia) - https://www.lalamove.com/18. VOYEJ (PT Lima Mahakarya Adabi) - https://www.voyejstore.com/19. MAHARANI Handicraft (CV Maharani) - http://maharanihandicraft.com/20. Metrox Group (PT Metrox Group) - https://metroxgroup.com/21. Orchi (Orchi Fried Chicken) - http://www.orchi-indonesia.com/22. PayFazz (PT Payfazz) - https://www.payfazz.com/23. PORTER (PT Porter Primalayan Utama) - https://porter.id/24. REALTA (PT Realta Chakradarma) - https://www.realta.co.id/25. RES Advisory (PT Resendriya Esa Stratindo) - http://realestatestrategy.co.id/26. Wake Cup (PT Solomen Utama) - https://wakecupindonesia.com/27. Studio Antelope (PT Studio Antelope Indonesia) - https://studioantelope.com/28. UrbanHire (Urbanhire) - https://www.urbanhire.com/29. Weddingku (Weddingku Group) - https://www.weddingku.com/About SME100 AwardsThe SME100 Awards is an Annual Recognition programme naming the fastest moving businesses of the SME sector. The Awards identify and recognise SMEs based on a basket of quantitative and qualitative criteria with a focus on growth (turnover, profit and market share) and resilience (best practices, sustainability and vision). The SME100 Awards serve as a pinnacle of trust and benchmark of reliability among business owners. Be it business ventures, investors, or clients foreign and domestic alike, the SME100 Awards have become a beacon of attention on all platforms. For more information, please visit http://sme100.asia.Available in Malaysia and Singapore, SME Magazine has managed to uphold prestige for the dynamic market of SMEs through the SME100 Awards. See https://smemagazine.asia. Copyright 2019 ACN Newswire. All rights reserved. www.acnnewswire.com
-
Netshoes Announces the Consummation of the Merger with Magazine Luiza
SÃO PAULO--(BUSINESS WIRE)--Netshoes (Cayman) Limited (the “Company”) announces today the consummation of the previously announced merger with a Magazine Luiza wholly-owned subsidiary (the “Merging Company”) (the “Merger”) as a result of all conditions precedent for the consummation of this merger having been satisfied, including approval by (i) Brazilian anti-trust authorities and (ii) a 90.32% favorable vote by shareholders present, either in person or by proxy, at the Company’s extraordinary general meeting of shareholders held on June 14, 2019. Pursuant to the terms of this transaction, the Merging Company merged with and into the Company, with the Company continuing as the surviving company (the “Surviving Company”) and as a wholly owned subsidiary of Magazine Luiza S.A. As a result of the consummation of the Merger, the Company’s shareholders, other than those who have validly exercised their statutory right to dissent to the merger, will be entitled to receive the merger consideration of US$3.70 in cash per common share, without interest and less any applicable withholding taxes (the “Merger Consideration”). Magazine Luiza and the Surviving Company will now cause the paying agent to mail to each holder of record of common shares, (i) transmittal materials, including a letter of transmittal in customary form as agreed by Magazine Luiza and the Company and (ii) instructions for surrendering book-entry common shares in exchange for the Merger Consideration. For further information with respect to payment procedures and the expected timeline for receipt of the Merger Consideration, see “The Merger Agreement—Payment Procedures” and the original form of agreement and plan of merger between the Company, Magazine Luiza S.A. and the Merging Company dated as of April 29, 2019, as amended, included in the Company’s information statement dated June 3, 2019 and previously furnished to the U.S. Securities and Exchange Commission. The Company has notified the New York Stock Exchange (“NYSE”) of the completion of the Merger, and trading in the Company’s common shares on the NYSE will cease as of the start of trading on June 17, 2019 and will be suspended effective before the opening of trading on that same day. Contacts Otavio Lyra, Investor Relations OfficerSão Paulo, BrazilPhone: +55 11 3028-3528Email: ir@netshoes.comhttp://investor.netshoes.com
